CD1C and neoplasm: Our strategy provides additional treatment options to the current arsenal of TCR- and CAR-T cells, particularly for AML, where no CAR has been yet approved due to major remaining challenges, including the off-tumor expression of currently identified CAR targets (CD33, CD34, CD123, FLT3)27, and is broadly applicable to either adult or pediatric B-ALL and AML patients owing to their common expression of CD1c molecules on blasts.